Qiagen (QGEN) Set to Release Quarterly Earnings on February 5th

Qiagen (NYSE:QGEN – Get Free Report) is anticipated to announce its quarterly earnings results on Wednesday, February 5th, after the stock market closes. Analysts predict that the company will report earnings of $0.60 per share, alongside revenue of approximately $518.54 million for the quarter. Individuals interested in participating in the conference call regarding these earnings can access it through the provided link.

Qiagen Stock Performance

As of Wednesday, QGEN stock opened at $45.15. The company's stock is currently under a 50-day moving average of $44.77 and a 200-day moving average of $44.37. Qiagen has a market capitalization of $10.30 billion, a PE ratio of 115.78, a price-to-earnings-growth ratio of 3.49, and a beta of 0.37. Over the past year, the stock has seen a low of $39.03 and a high of $47.93, reflecting its position in the market. Financial metrics show a quick ratio of 1.89, a current ratio of 2.17, and a manageable debt-to-equity ratio of 0.39.

Analysts' Ratings and Price Targets

Several analysts have provided updates on their ratings and price targets for Qiagen shares. For instance, HSBC Global Research upgraded the stock to a "hold" rating in a report dated October 17th. Earlier on the same day, they also adjusted their target price for Qiagen down from a "buy" rating to $49.00. Meanwhile, Jefferies Financial Group maintained a "buy" rating, increasing their target price from $42.00 to $54.00 as of December 10th. Morgan Stanley also reaffirmed their "equal weight" rating with a revised target price of $48.00, down from $50.00. In total, four analysts classify the stock as a hold, while five analysts advise to buy, resulting in a consensus rating of "Moderate Buy" and an average target price of $51.50 according to data from MarketBeat.com.

About Qiagen

QIAGEN NV is a leading holding company that specializes in providing Sample to Insight solutions, helping customers derive critical molecular insights from various biological samples. Their technologies focus on isolating and processing DNA, RNA, and proteins from diverse materials like blood and tissue.

Qiagen, Earnings, Stock